Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans

Kidney International

Volumn 83, Issue 1, 2013, Pages 114-120

  Lipkowitz, Michael S ^a   Freedman, Barry I ^b   Langefeld, Carl D ^b   Comeau, Mary E ^b   Bowden, Donald W ^b   Kao, W H Linda ^c   Astor, Brad C ^d   Bottinger, Erwin P ^e   Iyengar, Sudha K ^f   Klotman, Paul E ^g   Freedman, Richard G ^b   Zhang, Weijia ^e   Parekh, Rulan S ^c,h   Choi, Michael J ^c   Nelson, George W ⁱ   Winkler, Cheryl A ⁱ   Kopp, Jeffrey B ^j  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h HOSPITAL FOR SICK CHILDREN   (Canada)

ⁱ SAIC FREDERICK INC   (United States)

^j NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

more..

Author keywords

AASK (African American Study of Kidney Disease and Hypertension); APOL1; chronic kidney disease; ethnic minority; human genetics; hypertension

Indexed keywords

APOLIPOPROTEIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MYOSIN;

ADULT; AFRICAN AMERICAN; APOL1 GENE; ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; FEMALE; FOLLOW UP; GENE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC MARKER; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MYH9 GENE; PLESIOMORPHY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84871798567     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.263     Document Type: Article

References (21)

1. Kiberd BA, Clase CM. Cumulative risk for developing end-stage renal disease in the US population. J Am Soc Nephrol 2002; 13: 1635-1644.
2. US Renal Data System, USRDS. Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2011.
3. Kao WH, Klag MJ, Meoni LA et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008; 40: 1185-1192.
4. Kopp JB, Smith MW, Nelson GW et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40: 1175-1184.
5. Freedman BI, Hicks PJ, Bostrom MA et al. Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int 2009; 75: 736-745.
6. Genovese G, Friedman DJ, Ross MD et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329: 841-845.
7. Tzur S, Rosset S, Shemer R et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 2010; 128: 345-350.
8. Cooke JN, Bostrom MA, Hicks PJ et al. Polymorphisms in MYH9 are associated with diabetic nephropathy in European Americans. Nephrol Dial Transplant 2012; 27: 1505-1511.
9. O'Seaghdha CM, Parekh RS, Hwang SJ et al. The MYH9/APOL1 region and chronic kidney disease in European-Americans. Hum Mol Genet 2011; 20: 2450-2456.
10. Wright Jr JT, Kusek JW, Toto RD et al. Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials 1996; 17: 3S-16S.
11. Appel LJ, Wright Jr JT, Greene T et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363: 918-929.
12. Fogo A, Breyer JA, Smith MC et al. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. Kidney Int 1997; 51: 244-252.
13. Appel LJ, Wright Jr JT, Greene T et al. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med 2008; 168: 832-839.
14. Shulman NB, Ford CE, Hall WD et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 1989; 13: I80-I93.
15. Walker WG, Neaton JD, Cutler JA et al. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA 1992; 268: 3085-3091.
16. Marcantoni C, Ma LJ, Federspiel C et al. Hypertensive nephrosclerosis in African Americans vs. Caucasians. Kidney Int 2002; 62: 172-180.
17. Reeves-Daniel AM, DePalma JA, Bleyer AJ et al. The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant 2011; 11: 1025-1030.
18. Wright Jr JT, Bakris G, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431.
19. Chen Y, Lipkowitz MS, Salem RM et al. Progression of chronic kidney disease: adrenergic genetic influence on glomerular filtration rate decline in hypertensive nephrosclerosis. Am J Nephrol 2010; 32: 23-30.
20. Fung MM, Salem RM, Lipkowitz MS et al. Methylenetetrahydrofolate reductase (MTHFR) polymorphism A1298C (Glu429Ala) predicts decline in renal function over time in the African-American Study of Kidney Disease and Hypertension (AASK) Trial and Veterans Affairs Hypertension Cohort (VAHC). Nephrol Dial Transplant 2012; 27: 197-205.
21. Ashley-Koch AE, Okocha EC, Garrett ME et al. MYH9 and APOL1 are both associated with sickle cell disease nephropathy. Br J Haematol 2011; 155: 386-394.